COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS

被引：0
|
作者：
Walter, E. [1 ]
Voit, M. [1 ]
Eichhober, G. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV42
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
    Walter, Evelyn
    Voit, Marco
    Eichhober, Gerald
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 265 - 275
  • [2] Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
    Lee, Soyon
    Mullin, Rachel
    Blazawski, Jon
    Coleman, Craig I.
    PLOS ONE, 2012, 7 (10):
  • [3] COST-EFFECTIVENESS OF APIXABAN COMPARED TO ASPIRIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Hagstrom, Kelly
    Meng, Joy
    Kluger, Jeffrey
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E596 - E596
  • [4] Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
    Lip, Gregory Y. H.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Chalkiadaki, Corina
    Liu, Xianchen
    Kuznik, Andreas
    Lawrence, Jack
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2476 - 2488
  • [5] Cost-effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
    Pradelli, Lorenzo
    Calandriello, Mario
    Di Virgilio, Roberto
    Bellone, Marco
    Tubaro, Marco
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 (04) : 101 - 112
  • [6] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Oyaguez, Itziar
    Suarez, Carmen
    Luis Lopez-Sendon, Jose
    Ramon Gonzalez-Juanatey, Jose
    de Andres-Nogales, Fernando
    Suarez, Jorge
    Polanco, Carlos
    Soto, Javier
    PHARMACOECONOMICS-OPEN, 2020, 4 (03) : 485 - 497
  • [7] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Itziar Oyagüez
    Carmen Suárez
    José Luis López-Sendón
    José Ramón González-Juanatey
    Fernando de Andrés-Nogales
    Jorge Suárez
    Carlos Polanco
    Javier Soto
    PharmacoEconomics - Open, 2020, 4 : 485 - 497
  • [8] Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin
    Lee, Soyon
    Anglade, Moise W.
    Meng, Joy
    Hagstrom, Kelly
    Kluger, Jeffrey
    Coleman, Craig I.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2012, 5 (04): : 472 - 479
  • [9] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [10] COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS FOR THE PREVENTION OF STROKE: AN ANALYSIS OF PATIENTS WITH ATRIAL FIBRILLATION IN GREECE
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A525 - A525
12345